BG108537A - Единична доза азитромицин - Google Patents
Единична доза азитромицин Download PDFInfo
- Publication number
- BG108537A BG108537A BG108537A BG10853704A BG108537A BG 108537 A BG108537 A BG 108537A BG 108537 A BG108537 A BG 108537A BG 10853704 A BG10853704 A BG 10853704A BG 108537 A BG108537 A BG 108537A
- Authority
- BG
- Bulgaria
- Prior art keywords
- dose
- azithromycin
- use according
- treatment
- single dose
- Prior art date
Links
- 229960004099 azithromycin Drugs 0.000 title claims abstract description 44
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 44
- 206010057190 Respiratory tract infections Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims description 23
- 208000022760 infectious otitis media Diseases 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 description 16
- 241000606768 Haemophilus influenzae Species 0.000 description 8
- 206010033078 Otitis media Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000588655 Moraxella catarrhalis Species 0.000 description 4
- 210000000959 ear middle Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000011556 gerbil model Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 210000003454 tympanic membrane Anatomy 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000754835 Sapovirus isolates Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31386701P | 2001-08-21 | 2001-08-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG108537A true BG108537A (bg) | 2005-02-28 |
Family
ID=23217490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG108537A BG108537A (bg) | 2001-08-21 | 2004-01-21 | Единична доза азитромицин |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US20030148964A1 (cs) |
| EP (1) | EP1418924A2 (cs) |
| JP (1) | JP2005501862A (cs) |
| KR (1) | KR20040032942A (cs) |
| AP (1) | AP1729A (cs) |
| BG (1) | BG108537A (cs) |
| BR (1) | BR0211830A (cs) |
| CA (1) | CA2458135A1 (cs) |
| CZ (1) | CZ2004232A3 (cs) |
| EA (1) | EA200400214A1 (cs) |
| EC (1) | ECSP044985A (cs) |
| GE (1) | GEP20063812B (cs) |
| HR (1) | HRP20040163A2 (cs) |
| HU (1) | HUP0401332A2 (cs) |
| IL (1) | IL159585A0 (cs) |
| IS (1) | IS7092A (cs) |
| MA (1) | MA27059A1 (cs) |
| MX (1) | MXPA04001605A (cs) |
| OA (1) | OA12845A (cs) |
| PL (1) | PL367888A1 (cs) |
| SK (1) | SK1012004A3 (cs) |
| TN (1) | TNSN04035A1 (cs) |
| WO (1) | WO2003018031A2 (cs) |
| YU (1) | YU8804A (cs) |
| ZA (1) | ZA200400804B (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1648473B1 (en) * | 2003-07-24 | 2009-01-28 | PLIVA HRVATSKA d.o.o. | Single dose fast dissolving azithromycin |
| ATE399536T1 (de) | 2003-12-04 | 2008-07-15 | Pfizer Prod Inc | Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten |
| JP2007513147A (ja) | 2003-12-04 | 2007-05-24 | ファイザー・プロダクツ・インク | 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法 |
| US6984403B2 (en) | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
| CA2547597A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate compositions with improved stability |
| US7468428B2 (en) | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
| US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
| ES2798263T3 (es) | 2005-12-08 | 2020-12-10 | Insmed Inc | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US20090005326A1 (en) * | 2007-06-26 | 2009-01-01 | Idexx Laboratories, Inc. | Single dose roxithromycin |
| US20090197956A1 (en) * | 2008-02-04 | 2009-08-06 | Arbor Pharmaceuticals, Inc. | Treatment of acute otitis media with xylitol and n-acetylcysteine |
| WO2009114810A2 (en) * | 2008-03-14 | 2009-09-17 | The Florida International Uinversity Board Of Trustees | Use of ellagitannins as inhibitors of bacterial quorum sensing |
| WO2012170356A1 (en) | 2011-06-04 | 2012-12-13 | Rochester General Hospital Research Institute | Compositions and methods related to p6 of haemophilus influenzae |
| WO2014085526A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| PL3142643T3 (pl) | 2014-05-15 | 2019-12-31 | Insmed Incorporated | Sposoby leczenia zakażeń płuc prątkami niegruźliczymi |
| EP3773505A4 (en) | 2018-03-30 | 2021-12-22 | Insmed Incorporated | PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS |
| AU2019262117C1 (en) | 2018-05-02 | 2024-12-05 | Insmed Incorporated | Methods for the manufacture of liposomal drug formulations |
| US20230149428A1 (en) * | 2020-02-14 | 2023-05-18 | Asklepios Biopharmaceutical, Inc. | Method of treating gene therapy associated toxicity with antibiotics |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US53264A (en) * | 1866-03-20 | Improved ditching-machine | ||
| SI7910768A8 (en) * | 1979-04-02 | 1996-06-30 | Pliva Pharm & Chem Works | Process for pripering 11-aza-4-0-cladinosyl-6-0-desosaminyl-15-ethyl- 7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl- oxacyclopentadecane-2-one and their derivatives |
| SI8110592A8 (en) * | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| RO107257B1 (ro) * | 1987-07-09 | 1993-10-30 | Pfizer | Procedeu de obtinere a unui dihidrat de azitromicina, cristalin |
| WO1989002271A1 (en) * | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
| YU45590A (sh) * | 1990-03-07 | 1992-07-20 | PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o. | Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje |
| TW271400B (cs) * | 1992-07-30 | 1996-03-01 | Pfizer | |
| ES2104386T3 (es) * | 1993-05-19 | 1997-10-01 | Pfizer | Compuesto intermedio para la acitromicina. |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| NZ283160A (en) * | 1994-05-06 | 1998-07-28 | Pfizer | Azithromycin in a controlled release dosage form for treating microbiol infections |
| HRP980189B1 (en) * | 1998-04-06 | 2004-04-30 | Pliva Pharm & Chem Works | Novel 15-membered lactams ketolides |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| US20040053264A1 (en) * | 2002-02-01 | 2004-03-18 | Park Sung Sup | Clinical panel assay using DNA chips |
-
2002
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 EP EP02753170A patent/EP1418924A2/en not_active Withdrawn
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 CA CA002458135A patent/CA2458135A1/en not_active Abandoned
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/en not_active Ceased
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
-
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
-
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
-
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005501862A (ja) | 2005-01-20 |
| IS7092A (is) | 2003-12-23 |
| US20040023898A1 (en) | 2004-02-05 |
| IL159585A0 (en) | 2004-06-01 |
| ECSP044985A (es) | 2004-04-28 |
| US20050250712A1 (en) | 2005-11-10 |
| US6987093B2 (en) | 2006-01-17 |
| CZ2004232A3 (cs) | 2005-10-12 |
| US7067493B2 (en) | 2006-06-27 |
| EP1418924A2 (en) | 2004-05-19 |
| ZA200400804B (en) | 2005-05-03 |
| HUP0401332A2 (hu) | 2004-11-29 |
| WO2003018031A3 (en) | 2003-10-02 |
| WO2003018031A2 (en) | 2003-03-06 |
| EA200400214A1 (ru) | 2004-06-24 |
| MXPA04001605A (es) | 2004-07-08 |
| AP1729A (en) | 2007-03-26 |
| AP2004002968A0 (en) | 2004-03-31 |
| YU8804A (sh) | 2006-08-17 |
| MA27059A1 (fr) | 2004-12-20 |
| PL367888A1 (en) | 2005-03-07 |
| BR0211830A (pt) | 2004-09-08 |
| KR20040032942A (ko) | 2004-04-17 |
| US20030148964A1 (en) | 2003-08-07 |
| HRP20040163A2 (en) | 2005-02-28 |
| CA2458135A1 (en) | 2003-03-06 |
| TNSN04035A1 (fr) | 2006-06-01 |
| GEP20063812B (en) | 2006-05-10 |
| SK1012004A3 (sk) | 2005-04-01 |
| OA12845A (en) | 2006-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG108537A (bg) | Единична доза азитромицин | |
| McCracken | The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis | |
| Weightman et al. | Traditional Chinese acupuncture as an antiemetic | |
| CN106620649A (zh) | 使用单剂量奥利万星的治疗方法 | |
| Amin | Biological assessment of ozone therapy on experimental oral candidiasis in immunosuppressed rats | |
| Marchi | Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis | |
| Vidal et al. | Prophylactic inhibition of colonization by Streptococcus pneumoniae with the secondary bile acid metabolite deoxycholic acid | |
| Marshak et al. | Recurrent pneumococcal otitis media in the chinchilla: a longitudinal study | |
| McLinn | Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review | |
| Smilack et al. | Mycoplasma pneumoniae pneumonia and clindamycin therapy: failure to demonstrate efficacy | |
| McCarty | A multicenter, open label trial of azithromycin for the treatment of children with acute otitis media | |
| Lari et al. | Comparison of cefuroxime and co-amoxiclav in the treatment of acute sinusitis in a sample of the Iranian population | |
| CN114375200A (zh) | 治疗传染病的药物和方法 | |
| Bentley et al. | Lincomycin in the treatment of penicillin-resistant staphylococcal infections in children | |
| AU2002313574A1 (en) | Single dose azithromycin for treating respiratory infections | |
| US20250120929A1 (en) | Method of treating virus-associated infection using acetaminophen | |
| Barlow et al. | Infectious diseases and tropical medicine | |
| Ruiz-Bedoya et al. | 191. High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis | |
| RU2180532C2 (ru) | Способ лечения папилломатоза | |
| Flume | A role for aerosolized antibiotics | |
| Shimizu et al. | The haemodialysis patient who developed acute respiratory distress syndrome after a trip to a hot spring spa. | |
| Dandekar et al. | Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model | |
| Mattos Filho et al. | Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin: in vivo study in rats | |
| Gill et al. | 1244. Assessment of the In Vivo Activity of Human-Simulated Exposure of WCK 4282 (High Dose Cefepime [FEP]-Tazobactam [TZB]) against Enterobacterales (EB) and Pseudomonas aeruginosa (PA) in the Neutropenic Murine Thigh Infection Model | |
| Golhar et al. | CORONA VIRUS2019: INTRODUCTION AND ITS TREATMENTS |